[
  {
    "ts": null,
    "headline": "Pfizer (PFE) Laps the Stock Market: Here's Why",
    "summary": "Pfizer (PFE) closed the most recent trading day at $22.15, moving +0.48% from the previous trading session.",
    "url": "https://finnhub.io/api/news?id=acc72bda521f62ed10879ac7a01d5aa3f1b680c4bc6f8d9154b8dc0e9c938748",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744926316,
      "headline": "Pfizer (PFE) Laps the Stock Market: Here's Why",
      "id": 133964667,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) closed the most recent trading day at $22.15, moving +0.48% from the previous trading session.",
      "url": "https://finnhub.io/api/news?id=acc72bda521f62ed10879ac7a01d5aa3f1b680c4bc6f8d9154b8dc0e9c938748"
    }
  },
  {
    "ts": null,
    "headline": "US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years",
    "summary": "On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). In June 2024, ACIP postponed a vote on a recommendation for adults aged 50-59 at increased risk for RSV-LRTD until additional data becomes available. The update includes Pfizer Inc.’s (NYSE:PFE) Abrysvo (Respiratory Syncyt",
    "url": "https://finnhub.io/api/news?id=2ab839781469cfe311b059591d7beedf96718fc8d15d7382335e818924792f57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744918270,
      "headline": "US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years",
      "id": 133964668,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). In June 2024, ACIP postponed a vote on a recommendation for adults aged 50-59 at increased risk for RSV-LRTD until additional data becomes available. The update includes Pfizer Inc.’s (NYSE:PFE) Abrysvo (Respiratory Syncyt",
      "url": "https://finnhub.io/api/news?id=2ab839781469cfe311b059591d7beedf96718fc8d15d7382335e818924792f57"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer Inc. (PFE) the Best Large-Cap Value Stock to Buy as the Recession Hits?",
    "summary": "We recently published a list of 15 Best Large-Cap Value Stocks to Buy as the Recession Hits. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best large-cap value stocks to buy as the recession hits. Goldman Sachs highlighted that equities around the world traded in and […]",
    "url": "https://finnhub.io/api/news?id=6cdfe13a3b58f7dc11cf307f616b80b1f24f6d3ae424abe526c1fa92151cfb8c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744915820,
      "headline": "Is Pfizer Inc. (PFE) the Best Large-Cap Value Stock to Buy as the Recession Hits?",
      "id": 133964669,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently published a list of 15 Best Large-Cap Value Stocks to Buy as the Recession Hits. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best large-cap value stocks to buy as the recession hits. Goldman Sachs highlighted that equities around the world traded in and […]",
      "url": "https://finnhub.io/api/news?id=6cdfe13a3b58f7dc11cf307f616b80b1f24f6d3ae424abe526c1fa92151cfb8c"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (NYSE:PFE) Gets CDC Recommendation to Expand ABRYSVO Vaccine Use for RSV Prevention",
    "summary": "Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at increased risk. Despite this positive development, Pfizer's shares saw a 2% decline over the past week. This move is in line with broader market trends, as the market dropped by 3% during the same period. The company's decision to halt development of Danuglipron, an oral weight loss drug, due to safety concerns, may have also added weight to the downward pressure on its...",
    "url": "https://finnhub.io/api/news?id=1efbf8e90792db78acdfec87466dad1c295ae5454868ec0e3c85d4cb5ba82560",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744910734,
      "headline": "Pfizer (NYSE:PFE) Gets CDC Recommendation to Expand ABRYSVO Vaccine Use for RSV Prevention",
      "id": 133958641,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at increased risk. Despite this positive development, Pfizer's shares saw a 2% decline over the past week. This move is in line with broader market trends, as the market dropped by 3% during the same period. The company's decision to halt development of Danuglipron, an oral weight loss drug, due to safety concerns, may have also added weight to the downward pressure on its...",
      "url": "https://finnhub.io/api/news?id=1efbf8e90792db78acdfec87466dad1c295ae5454868ec0e3c85d4cb5ba82560"
    }
  },
  {
    "ts": null,
    "headline": "Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential",
    "summary": "Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential",
    "url": "https://finnhub.io/api/news?id=23b060bab3e63c2acac03f90f8176364f2746e75380bbd95fee77f0345e8f839",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744909654,
      "headline": "Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential",
      "id": 133960246,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=23b060bab3e63c2acac03f90f8176364f2746e75380bbd95fee77f0345e8f839"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings?",
    "summary": "Bristol Myers is looking to turn its business around, banking on the strong uptake of new drugs. However, the 2025 outlook is not bright and we recommend investors to wait and watch for now.",
    "url": "https://finnhub.io/api/news?id=031cf3e447d399bc99ff542b3041b8f029a6fde6e9a9810346a339c9c8441795",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744909560,
      "headline": "Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings?",
      "id": 133964670,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Bristol Myers is looking to turn its business around, banking on the strong uptake of new drugs. However, the 2025 outlook is not bright and we recommend investors to wait and watch for now.",
      "url": "https://finnhub.io/api/news?id=031cf3e447d399bc99ff542b3041b8f029a6fde6e9a9810346a339c9c8441795"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results",
    "summary": "Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results",
    "url": "https://finnhub.io/api/news?id=d89de58e5898b61cd6dec99e31cc4401f1568e8c8026a14a83905925769e4770",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744897502,
      "headline": "Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results",
      "id": 133958177,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=d89de58e5898b61cd6dec99e31cc4401f1568e8c8026a14a83905925769e4770"
    }
  },
  {
    "ts": null,
    "headline": "GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59",
    "summary": "The U.S. CDC's Advisory Committee recommends the use of GSK and Pfizer's RSV vaccines in adults aged 50-59 who are at high risk of severe RSV disease.",
    "url": "https://finnhub.io/api/news?id=00e5c44d6d5fbc7c2b2331d33f4d4b00a3845fd3429759e5090daef9f33f40a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744896000,
      "headline": "GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59",
      "id": 133958643,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The U.S. CDC's Advisory Committee recommends the use of GSK and Pfizer's RSV vaccines in adults aged 50-59 who are at high risk of severe RSV disease.",
      "url": "https://finnhub.io/api/news?id=00e5c44d6d5fbc7c2b2331d33f4d4b00a3845fd3429759e5090daef9f33f40a7"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback",
    "summary": "JNJ beats first-quarter estimates for earnings and sales. PFE ends the development of the weight loss pill danuglipron.",
    "url": "https://finnhub.io/api/news?id=3f5eeaf98e7d70d86a0af06eaf3c65119ad031e0236e87c103bf438f047091f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744895700,
      "headline": "Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback",
      "id": 133958644,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "JNJ beats first-quarter estimates for earnings and sales. PFE ends the development of the weight loss pill danuglipron.",
      "url": "https://finnhub.io/api/news?id=3f5eeaf98e7d70d86a0af06eaf3c65119ad031e0236e87c103bf438f047091f2"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Soars After Weight-Loss Pill Results Rival Ozempic’s",
    "summary": "(Bloomberg) -- Eli Lilly & Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative to injections.Most Read from BloombergTrump Signs Executive Orders on Federal Purchasing, Office SpaceHow Did This Suburb Figure Out Mass Transit?DOGE Places Entire Staff of Federal Homelessness Agency on LeaveWhy the Best Bike Lanes Always Get BlamedLA County Floats Leaner Budget Burdened by Fire",
    "url": "https://finnhub.io/api/news?id=f8ffd3456f7535c95fa226cbc333cfd2e3700aeadf37c04bdacf608f6fe6c0f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744890933,
      "headline": "Lilly Soars After Weight-Loss Pill Results Rival Ozempic’s",
      "id": 133942478,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Eli Lilly & Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative to injections.Most Read from BloombergTrump Signs Executive Orders on Federal Purchasing, Office SpaceHow Did This Suburb Figure Out Mass Transit?DOGE Places Entire Staff of Federal Homelessness Agency on LeaveWhy the Best Bike Lanes Always Get BlamedLA County Floats Leaner Budget Burdened by Fire",
      "url": "https://finnhub.io/api/news?id=f8ffd3456f7535c95fa226cbc333cfd2e3700aeadf37c04bdacf608f6fe6c0f4"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Soars. Why a Weight-Loss Pill Trial Is Giving It a Boost.",
    "summary": "Eli Lilly Stock Soars. Why a Weight-Loss Pill Trial Is Giving It a Boost.",
    "url": "https://finnhub.io/api/news?id=99271e7159f2452ff254a1f3d8690c362475c0555a59baf0798a2fe751bb5b2e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744885080,
      "headline": "Eli Lilly Stock Soars. Why a Weight-Loss Pill Trial Is Giving It a Boost.",
      "id": 133945452,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Eli Lilly Stock Soars. Why a Weight-Loss Pill Trial Is Giving It a Boost.",
      "url": "https://finnhub.io/api/news?id=99271e7159f2452ff254a1f3d8690c362475c0555a59baf0798a2fe751bb5b2e"
    }
  },
  {
    "ts": null,
    "headline": "My Dividend Stock Portfolio: New All-Time Dividend Record In March - 100 Holdings With 15 Buys",
    "summary": "My Dividend Stock Portfolio: New All-Time Dividend Record In March - 100 Holdings With 15 Buys",
    "url": "https://finnhub.io/api/news?id=3583de69a5b9294d49cfc850c02d9e183a0af145eb6a1cde6d77ee1e1a833ab0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744877400,
      "headline": "My Dividend Stock Portfolio: New All-Time Dividend Record In March - 100 Holdings With 15 Buys",
      "id": 133942183,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=3583de69a5b9294d49cfc850c02d9e183a0af145eb6a1cde6d77ee1e1a833ab0"
    }
  },
  {
    "ts": null,
    "headline": "Trump Tariff Plunge: 3 Phenomenal Stocks to Buy at Bargain Prices Right Now",
    "summary": "Tariff uncertainty has created an ideal opportunity for long-term investors to pounce.",
    "url": "https://finnhub.io/api/news?id=a8d371d2b237ed4642285ce1514aed3c9f36fce9ebd133db471f338943e420ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744876260,
      "headline": "Trump Tariff Plunge: 3 Phenomenal Stocks to Buy at Bargain Prices Right Now",
      "id": 133942607,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Tariff uncertainty has created an ideal opportunity for long-term investors to pounce.",
      "url": "https://finnhub.io/api/news?id=a8d371d2b237ed4642285ce1514aed3c9f36fce9ebd133db471f338943e420ff"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Risks Priced In, Buy The Exceptional Valuation And Yield",
    "summary": "Pfizer: Risks Priced In, Buy The Exceptional Valuation And Yield",
    "url": "https://finnhub.io/api/news?id=ffc95d61ccea4d9bc9524266bd21209583d66a3a7ea20f87ea1108e0bd259823",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744851524,
      "headline": "Pfizer: Risks Priced In, Buy The Exceptional Valuation And Yield",
      "id": 133939369,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=ffc95d61ccea4d9bc9524266bd21209583d66a3a7ea20f87ea1108e0bd259823"
    }
  }
]